

# CSL Research Acceleration Initiative

## Seeking Expressions of Interest from Research Organisations

### WHY COLLABORATE WITH CSL?



**Global** Capabilities  
on your doorstep



**Work** with one of  
the world's leading  
biotech companies



**Funding** for  
successful proposals



**Access** to commercial  
R&D, clinical, intellectual  
property, marketing and  
manufacturing expertise



**Accelerate** translation  
of your research to  
deliver new therapies  
to patients

CSL is a leading global biotech company that develops and delivers innovative biotherapies to help people living with life-threatening medical conditions live full lives. CSL's Research Acceleration Initiative aims to fast-track discovery of innovative biotherapies through partnerships between CSL and global research organisations. These partnerships provide funding and access to industry resources for scientists working on novel biotherapeutic strategies in CSL's therapeutic areas. Expressions of interest are sought from Business Development / Commercialisation representatives across global research organisations that wish to participate in the 2021 CSL Research Acceleration Initiative.

The 2021 Research Acceleration Initiative will focus on research projects that span a **CSL Therapeutic Area** and a **Focus Area**, and that are amenable to or include a **Modality** listed below:

#### THERAPEUTIC AREAS

*(emphasis on rare disease)*

- Immunology
- Hematology
- Respiratory
- Cardiovascular/Metabolic
- Transplant

#### FOCUS AREAS

- Novel drug targets
- Novel therapeutic candidates
- Novel strategies for treating disease

#### MODALITIES

- Antibodies
- Protein therapeutics
- Gene therapies
- Cell therapies
- Small molecules **not** of interest

# CSL Research Acceleration Initiative

## Additional Information

---

### Register your research organisation

BD / Commercialisation representatives from research organisations (universities, medical research institutes, hospitals) are invited to register their organisation's interest to participate in the 2021 Research Acceleration Initiative by **emailing [RAI@cslbehring.com](mailto:RAI@cslbehring.com) by 1st December 2020**.

### Assign your primary contact

CSL requests that each research organisation nominate **one** BD / Commercialisation representative to be assigned as the primary contact for CSL.

### Calls for scientific proposals

CSL will work with nominated BD / Commercialisation representatives from participating research organisations to seek scientific proposals that span a CSL Therapeutic Area and a CSL Focus Area, and that are amenable to or include a CSL Modality listed over the page. Scientists who wish to apply will be asked to submit a 300 word online pre-application that outlines their proposal. It is anticipated that online submission of pre-applications will open in January 2021.

### Limitations on submissions

There is no limit on the number of pre-applications that can be submitted by registered research organisations.

### Funding

Successful applicants will receive up to CHF 180k / EUR 170k per year for up to two years (maximum CHF 360k / EUR 340k funding) to accelerate translation of their research. Funding is subject to successful negotiation and execution of a research collaboration agreement between CSL and research organisation.

